Phaseline

Companies › Nuwacell Biotechnologies

Nuwacell Biotechnologies: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NCR201
Allogeneic dopaminergic neural precursor cell therapy
–Phase 1Parkinson DiseaseDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06978920NCR201Phase 1Parkinson DiseaseNeurologyDec 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.